alternative RNA transcript is 96 nucleotides longer than the major transcript as a result of alternative splicing of intron 10 sequences. The protein expected to be generated from the p53as transcript is 9 amino acids shorter than the major p53 protein and has 17 different amino acids at the carboxyl terminus. We report here that p53as protein exists in nontransformed and malignant epidermal cells and is localized to the nucleus. In addition, p53as protein is preferentially expressed during the G2 phase of the cell cycle and in cells with greater than G2 DNA content compared with the major p53 protein, which is preferentially expressed in GI. The p53as immunoreactivity is elevated and shifted to the G1 phase of the cell cycle following actinomycin D treatment of nontransformed cells but not malignant cells. In view of the dimerization and tetramerization of p53 protein which may be necessary for its DNA binding and transcriptional activation activities, the presence of p53as protein in cells has important implications for understanding the physiological function(s) of the p53 gene.
The tumor suppressor gene p53 is the most frequently altered gene in human cancers, mutations or deletions of p53 being detected in over half of all tumors (44) . Introduction of wild-type (wt) p53 into a variety of transformed or tumor cells arrests their growth (7, 11) or induces programmed cell death (apoptosis) (51, 52) . These observations suggest that defects in the p53 gene are acquired during cancer development along multiple initiation and promoting pathways and that cells with various accumulated defects are sensitive to tumor growth arrest by wt p53 protein, making this gene of widespread interest.
Human and mouse p53 share an 81% identity at the protein level, with a highly acidic N terminus, a basic C terminus, and a central region containing uncharged amino acids (40) . The studies of the p53 gene in cells, tissues, or cell-free systems have led to the assignment of certain conserved functional domains, as summarized by Vogelstein and Kinzler (reference 45 and references therein) (Fig. 1) . Heat shock protein binding and transcriptional activation domains are found near the N terminus, while nuclear localization signals and regions required for heat shock protein binding (35) are located near the C terminus. Residues important for self-association of p53 are present within the 47 C-terminal amino acids (13, 19, 31) , including acidic and basic residues important for dimerization and tetramerization, respectively (15, 43) . Several monoclonal antibodies to mouse p53 protein are differentially reactive to wt p53 in the normal, tumor-suppressive conformation (PAb246), to denatured wt and mutant p53 (PAb421) (46, 50) , or to certain mutant p53 proteins (PAb240) (reference 42 and references therein). There are sites for phosphorylation by casein kinase II (serine 389) (28) and p34cdc2 kinase and for covalent linkage of 5.8S rRNA (12) . Studies using p53 protein generated in vitro, in bacteria, or in baculovirus systems have indicated that p53 probably binds to DNA as a tetramer (3, 41) and activates (10, 47, 53) or represses (39) We have previously reported that wt p53 is abnormally regulated early after malignant conversion in chemically transformed mouse epidermal cells, prior to any coding region mutations (16) . In squamous cell carcinomas from two independently initiated cell lineages, wt p53 RNA abundance is increased at the point of malignant conversion. Immunodetectable p53 protein (detected with monoclonal anti-p53 antibodies PAb421 and PAb246) is very low in one (17) about 25 to 33% of the level of the major p53 RNA form (17) . In addition, it was present at approximately the same ratio in the two independently derived epidermal carcinoma lines which overexpress p53 RNA (noted above) and thus appeared to be coordinately elevated with the major form of p53.
The translation of alternatively spliced p53 results in the substitution of 17 amino acids and in truncation of the regularly spliced form of p53 by 9 amino acids (Fig. 1) (22, 26, 38 (1, 120 Ci/mmol) for 4 h at 37°C in methionine-free minimum essential medium containing 2% (vol/vol) dialyzed calf serum. Labeled cells were lysed in buffer containing 1% (vol/vol) Nonidet P-40, 150 mM NaCl, 50 mM Tris (pH 8), and 1 mM phenylmethylsulfonyl fluoride for 30 min at 4°C and centrifuged at 10,000 x g for 10 (18) . A 500-bp PstI fragment of p53-422 was used for p53 detection (34) , and a 840-bp EcoRI-SalI fragment of pA6 was used for 7S RNA detection as a control for RNA loading (2) . Probes were labeled with [a-32P]dCTP by the random primer method, using a multiprime labeling kit (Amersham, Arlington Heights, Ill.). 32P-labeled probe was used at a final concentration of 1 x 106 to 2 x 106 cpm/ml. Differences in p53 RNA abundance were quantitated by densitometry of exposed films (Fastscan computing densitometer; Molecular Dynamics, Sunnyvale, Calif.) after adjustment for 7S RNA.
Flow cytometry. Cells permeabilized in suspension with 100% cold ethanol were exposed to anti-p53 antibodies as described above for indirect immunofluorescence except that the secondary reagent for anti-p53as was phycoerythrin (PE)-conjugated goat anti-rabbit IgM and IgG (FisherBiotech). Hoechst 33342 (1 ,ug/ml; bisbenzimide H; Calbiochem) was added 1 h prior to flow analysis for detection of DNA content. Analysis was performed on a FACSTAR+ dual SW argon laser system (Becton Dickinson Immunocytometry Systems, San Jose, Calif.) with the primary laser lasing at 488 nm at 200 mW and the secondary laser lasing at 350 nm at 50 mW. PE and Hoechst emissions were passed through discretion filters with band widths of 575 ± 13 and 424 ± 22 nm, respectively. Flow cytometry data were acquired by using Becton Dickinson standard acquisition software to exclude cell aggregates and debris and to collect single-cell events only. Data were analyzed with Lysys II software (Becton Dickinson Immunocytometry Systems).
RESULTS
To determine whether the pS3as protein was made in cells, a polyclonal antibody to the 17-amino-acid sequence unique to p53as was generated in rabbits. Rabbit serum collected at intervals after immunization was tested for reactivity to p53as peptide coated on ELISA plate wells (Fig. 2) ( Fig. 2) was affinity purified against the 17-amino-acid peptide. The reactivity (per 50 ng of antigen) of 10 ng of affinity-purified antibody was approximately equivalent to a 1/40,000 dilution of whole anti-p53as antiserum. Anti-p53as reactivity in the ELISA and indirect immunofluorescence assays was blocked competitively by preincubation of antibody with the p53as peptide.
Immunoprecipitation. To determine its reactivity with cellular proteins, affinity-purified antiserum to p53as was reacted with mouse epidermal cell lysates (Fig. 3) . A 53-kDa protein was immunoprecipitated by anti-p53as. This protein migrated slightly faster on 10% polyacrylamide gels than p53 protein immunoprecipitated by PAb421 (which binds to a carboxylterminal epitope absent in p53as). Rabbit polyclonal anti-p53 antibody CM5 recognized a broader band spanning the region containing more discrete PAb421 + and anti-p53as+ reactive forms.
Indirect immunofluorescence. The location and incidence of expression of p53as in cell populations grown on coverslips were determined by indirect immunofluorescence. As shown in Fig. 4 , nuclear staining was observed with affinity-purified anti-p53as antibody. This activity was completely blocked by competitive binding with p53as peptide (Fig. 4C) . Anti-p53as antibody reactivity in 291 nontransformed cells and carcinoma cells was always nuclear under the conditions of these assays (data for clone 119 are shown) and in this respect was like PAb246 antibody reactivity. This was true even in clones of 291.03RAT transfected with the pmMTval-135 temperaturesensitive mutant of p53, in which PAb421 reactivity was cytoplasmic as well as nuclear. These results suggest that like the major p53 form, wt p53as protein exerts its effects primarily in the nucleus. p53 expression in nontransformed cells and tumor cells. We reported previously that squamous cell carcinoma 291.03RAT expresses 3-fold more p53 mRNA and up to 10-fold less p53 protein (PAb421 and PAb246 antibody reactivity) than the progenitor 291 cells (16) . Comparison of the expression of p53as protein in these cell lines was done by immunoprecipitation. As shown in Fig. 5 , reactivity with anti-p53as antibody was detected in nontransformed 291 cells and carcinoma cells. The p53as-precipitable protein in these cell lines migrates slightly faster than the PAb421-and PAb246-precipitable proteins, as expected from the truncation of p53as by nine carboxy-terminal amino acids (expected to result in an approximately 1-kDa difference in molecular mass). As expected from previous studies (16) , immunoreactivity to all three anti-p53 antibodies was lower in 291.03RAT carcinoma cells than in normal cells. The ratio of immunoprecipitable protein in populations of proliferating cells versus differentiating 291 cells was higher for anti-p53as (5/1) and for PAb421 (2/1) than for PAb246 (1/1). Elevated PAb421 reactivity in proliferating populations also was noted by Milner (29) in studies of mouse lymphocytes. These results suggested that p53as protein might be differentially expressed relative to PAb421 and PAb246 death in severely damaged cells (27) . Flow cytometry was performed to determine whether p53as antigen activity was differentially expressed during the cell cycle. Cells which had been exposed to actinomycin D or solvent were stained with antibodies to p53as and PAb421 or PAb246, taking advantage of the different species of origin of the polyclonal and monoclonal antibodies to permit immunodetection of p53as and p53 antigens in the same cell. PE (red) conjugated to anti-rabbit immunoglobulin was used to recognize p53as, and FITC (green) conjugated to anti-mouse immunoglobulin was used to recognize PAb421 and PAb246. Coordinates were set on the basis of the fluorescence intensity in primary antibody controls ( Fig. 6A and 7A ) to detect events (single cells) positive for anti-p53as reactivity alone (region 1 [R1]), positive for antip53as and PAb421 or PAb246 (R2), negative for anti-p53as and positive for PAb421 or PAb246 (R3), and negative for both anti-p53as and PAb421 or PAb246 (R4). Cells positive for anti-p53as alone (Ri), when present, showed a distribution of DNA content similar to that of cells positive for p53as and PAb421 or PAb246. Competition with p53as peptide, but not an unrelated peptide, effectively blocked events detectable in Rl and R2 (shown for 291.05RAT in Fig. 6B , C, E, and F and for 291 cells in Fig. 7B , C, E, and F) without appreciably affecting the R3 events, verifying the specificity of the antip53as antibody for p53as protein and its lack of reactivity with the major p53 protein. Thousands of events from each region were collected for analysis of cell cycle distribution according to Hoechst area, represented in the histograms (Fig. 6G to I and 7G to I for R2, R3, and R4, respectively). The cell cycle distributions of actinomycin D-treated 291.05RAT cells (shown) and controls were essentially the same. The cells negative for both antibody reactivities (Fig. 61 and 71 ) and the PAb421+ p53as-cells (Fig. 6H and 7H) were distributed primarily in the G0/Gl phase of the cell cycle, while p53as+ cells ( Fig. 6G and 7G) were preferentially in the G2/M phase of the cycle. Particularly striking is the distribution of p53as+ cells in a tail, indicating DNA content in excess of that in G2/M cells. Since single cells only were collected for analysis, it is likely that such cells had undergone DNA synthesis or even nuclear division but failed to undergo cytokinesis. Inspection of p53as+ cells grown on coverslips revealed that most (approximately 85%) contained two or more nuclei (data not shown), supporting the conclusion that these carcinoma cells continued to synthesize DNA and to undergo nuclear division but failed to undergo cell division. Nontransformed 291 cells, cultured under conditions favoring proliferation (LC), were treated similarly for comparison with carcinoma cells (Fig. 7) . The p53as+ 291 cells (whether singly or also positive for PAb421) were preferentially in the G2/M stage, while PAb421 + cells were preferentially in Go/GI. Unlike the carcinoma cells, the p53as+ 291 cells observed on coverslips were mononucleated (data not shown). Nontransformed and carcinoma cells positive for PAb246 reactivity showed cell cycle distributions essentially the same as that of cells positive for PAb421.
The percentage distributions by cell cycle stage of nontransformed 291 and 291.05RAT carcinoma cells treated with actinomycin D or solvent controls are presented in Table 2 
DISCUSSION
p53as, a physiological variant of the tumor suppressor protein p53, has been detected in mouse epidermal cells containing the wt p53 gene. The fact that endogenous wt p53as protein has not been detected in cells before may be due to its low abundance and lack of reactivity with anti-p53 monoclonal antibody PAb421. We showed previously that the wt p53as mRNA is present in normal mouse tissues and in cultured mouse fibroblasts at 25 to 33% of the level of the major p53 RNA form (17) . The current studies demonstrated that the p53as protein exists in cells, was nuclear in location in normal epidermal and carcinoma cells, was differentially expressed in proliferating compared with differentiating cultures of nontransformed cells, was preferentially expressed in the G2 phase of the cell cycle, and was inducible along with PAb421-and PAb246-reactive p53 by actinomycin D.
The distribution of p53as+ cells in G2/M and >G2/M appears likely to reflect a growth arrest or maturation pathway, yet immunodetectable p53as was expressed preferentially in proliferating cells. This finding could suggest that p53as is involved in maintaining the balance between growth and maturation within epidermal cell populations. Even under conditions favoring proliferation (LC conditions; see Materials and Methods), basal (proliferation-associated) cell markers are lost with time after plating, and differentiating cells increase as a percentage of the total population (24 (23) . While the 291 cells are subtetraploid (26) , they appear to retain the capacity to generate a subpopulation of VOL. 14, 1994 on 6 . Expression of p53 (PAb421) and p53as antigen activities in 291.05RAT carcinoma cells. Cells were treated with 0.5 nM actinomycin D for 2 days and harvested by trypsinization. Cells were permeabilized and stained in suspension with anti-p53as (acp53as) and PAb421 antibodies (in the same tube) in all cases shown except for the primary antibody control (A). In the dot plots (A to F), the FLI fluorescence intensity on the x axis was FITC (green), used to visualize PAb421 reactivity, and the FL2 fluorescence intensity on the y axis was PE (red), used to visualize anti-p53as reactivity. Prior to incubation with cells, the anti-p53as antibody was exposed either to p53as peptide (C and F), which competitively removed the specific anti-p53as reactivity, or to an unrelated peptide (B, D, and E), which controlled for nonspecific binding to peptide, leaving only specific reactivity to p53as protein. Events collected by flow cytometry were single cells only as described in Materials and Methods. Coordinates were set on total cell data based on IgG2a and preimmune (Pre-I) controls to delineate four regions: negative for both antibodies (R4), positive for anti-p53as only (Rl), positive for PAb421 and anti-p53as (R2), and positive for PAb421 only (R3). The cell cycle distributions of events from regions R2, R3, and R4 are shown in the histograms in panels G to I. After collection of a file of 10,000 total events per tube (as shown in panels A to C), additional gates were set which excluded negative cells (R4) (as shown in dot blot E, used to generate the histogram for (43) demonstrated that loss of C-terminal basic residues permitted dimer formation of p53 protein but not tetramers, while Hainaut and Milner (15) showed that similarly, deletion of 25 C-terminal amino acids of p53 resulted in dimers but not higher-order complexes. Since p53 protein is thought to bind to DNA as a tetramer (3, 41) , restriction of p53as to dimer formation may influence its interactions with DNA.
Properties of the mutated form of alternatively spliced p53 protein translated in vitro from the M-8 cDNA clone (1) have been reported. Hainaut and Milner (15) observed that following in vitro translation, the mutant alternatively spliced p53 protein encoded by M-8 formed monomers and dimers but not tetramers. Like the mutant M-8 protein, wt p53as has lost the basic amino acids of the C terminus but retains the acidic amino acids shown to permit dimer formation. These results support the idea that wt p53as may have distinct properties from the major p53 protein form. However, the M-8 p53 cDNA sequence has a nucleotide substitution at nucleotide 395 resulting in a change from cysteine 132 to phenylalanine. Eliyahu et al. (9) reported that plasmids containing the M-8 p53 cDNA had transforming activity in transfected cells.
Mutations within this region without alternative splicing give rise to p53 proteins defective in tumor suppressor function and DNA binding (references 9, 11, and 45 and references therein). Thus, the M-8 protein has a mutation which affects its function apart from the C-terminal changes due to alternative splicing. p53 protein translated from cDNA clone M-8 does not react with PAb248 antibody, which like PAb246 is wt conformation specific, or, as a result of loss of the C-terminal epitope, PAb421 (48) . Since wt p53as has a distinct conformation compared with the mutated M-8 protein, functional properties such as DNA binding cannot be predicted from studies of M-8 protein and must be tested directly.
In addition to alterations in the oligomerization domain predicted from the studies described above, pS3as has lost the casein kinase II phosphorylation-5.8S rRNA binding site located at serine 389 (Fig. 1) . Loss of the phosphorylation site at serine 389 by mutation negates p53 antiproliferative activity (4, 28, 33) . Hupp The differential expression of p53 and p53as protein immunoreactivities during the cell cycle suggests that each has a distinct function. Perhaps p53 may prove to be within the class of transcription factors which generate two functionally distinct proteins by alternative splicing (14) . For example, in the case of mouse TFE3 (transcription factor E3) (which regulates immunoglobulin transcription by binding to promoter and enhancer regions), there is a longer and a shorter protein form. In the shorter form, amino acids predicted to form an amphipathic helix are absent and transcriptional activation activity is affected. The ability of such factors to heterodimerize amplifies the possibilities for regulation of expression of target genes.
It will be important to determine the activity of wt p53as in tumor suppression. While originally thought to be an oncogene because initial clones of p53 harbored mutations, cloning of wt p53 led to the recognition of its role as a tumor suppressor gene (9, 11) . The capacity of mutant p53 protein to drive wt p53 into the mutant conformation uncovered its potential as a dominant negative transforming gene (29, 31 ). Yet mutant p53 itself has transforming activity in cells which have no wt p53, suggesting direct activities of p53 in the regulation of proliferation (49 R3, 8,816 (F) . Note that the total numbers of events in panels E and F are comparable, indicating the specificity of the anti-p53as antibody for p53as antigen and lack of cross-reactivity with p53 antigen. The percentages of cells in each phase of the cell cycle and total events (n) for each region in the histograms shown were as follows: R2, GO/GI, 14 
